Acutaas Chemicals shares surged 13% to hit a record high of ₹3,797 on the National Stock Exchange (NSE) during Tuesday's intraday trading, significantly outperforming the broader market. According to Business Standard, the stock surpassed its previous high of ₹3,735 touched on July 6, 2026, demonstrating exceptional investor confidence following the company's strong September quarter results. The pharmaceutical company's market price has zoomed 116% in calendar year 2026, a stark contrast to the 9.4% decline in the Nifty 500 index during the same period. This remarkable performance positions Acutaas Chemicals as a standout performer in an otherwise tepid market environment, with the stock trading close to its 52-week high of ₹3,740.
According to Business Standard, Acutaas Chemicals delivered exceptional September quarter results that drove significant investor confidence. The company's revenue grew by 42.7% year-on-year to ₹436.9 crore from the previous year. Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) rose 84.6% YoY to ₹176.0 crore, while EBITDA margin improved to 40.3% compared to 31.1% in Q2FY26. The gross margin for the quarter improved significantly to 62.1%, up 637 basis points year-on-year. Profit after tax (PAT) for the quarter jumped 71.4% YoY to ₹123.1 crore, reflecting the company's strong operational performance across all key metrics. For the half-year period (H1 FY27), revenue from operations increased by 49.3% to ₹766.6 crore, up from ₹513.4 crore in H1 FY26, as reported by Acutaas Chemicals.
As reported by Business Standard, Acutaas Chemicals has revised its financial year 2027 guidance upward following the strong quarterly performance. The company increased its revenue growth guidance from 25% to around 30% for FY27, with management citing improved revenue visibility and a robust order pipeline as key confidence factors. Additionally, the company revised its EBITDA margin guidance higher to the 38-40% range for the full year. The management attributed the growth during the quarter to continued momentum in the Pharmaceutical Intermediates business, which was offset by softer performance in the Specialty Chemicals segment. According to Business Standard, a significant milestone during the quarter was the inauguration of the company's South Korea manufacturing facility ahead of schedule, which is equipped to produce high-purity chemicals for semiconductor applications. Gross profit for the quarter rose by 59.0% to ₹271.5 crore, with the gross margin improving to 62.1%, as reported by Acutaas Chemicals.
According to Business Standard, the CDMO business and core advanced intermediate business delivered robust growth during the quarter, while the specialty chemicals business remained subdued. The BFC business was impacted during the quarter due to change in ownership of the US customer. The company operates as a specialty chemicals manufacturer serving pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals, with core strength in research-driven development of advanced pharmaceutical intermediates. Acutaas Chemicals is well-positioned to capitalize on the Indian CDMO market expansion, valued at $8.52 billion in 2025 and projected to reach $16.53 billion by 2034, driven by increasing pharmaceutical outsourcing and the China+1 strategy adoption.
As reported by Business Standard, the company is positioned to benefit from India's semiconductor market growth, which was valued at $59.78 billion in 2025 and projected to reach $180.20 billion by 2034, growing at an 11.95% CAGR from 2026 to 2034. This expansion is fueled by government initiatives like the ₹76,000 crore PLI scheme and surging demand from AI, 5G, and electric vehicles. The Indian semiconductor ecosystem is experiencing massive industrial projects, including Tata Electronics' $11 billion fab and Micron's assembly facility in Gujarat, creating significant opportunities for specialty chemical manufacturers. The company noted that growth is accelerated by massive industrial projects and the digital economy scaling towards $1 trillion, with demand for ultrapure materials and specialized chemicals remaining a critical tailwind for the domestic chemical industry.
